Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
出版年份 2018 全文链接
标题
Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
作者
关键词
immunoliposomes, neuroblastoma cells, sepantronium bromide (YM155), targeted delivery
出版物
PHARMACEUTICAL RESEARCH
Volume 35, Issue 4, Pages -
出版商
Springer Nature
发表日期
2018-03-08
DOI
10.1007/s11095-018-2373-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Disialoganglioside GD2 as a therapeutic target for human diseases
- (2015) Maya Suzuki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles
- (2015) Dana C Baiu et al. Nanomedicine
- Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant
- (2014) Hiroki Kawano et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma
- (2014) M. Emmy M. Dolman et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
- (2014) X. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier
- (2014) Jianqin Lu et al. MOLECULAR PHARMACEUTICS
- Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
- (2014) Kohsuke Shakushiro et al. PHARMACEUTICAL RESEARCH
- Current and Future Strategies for Relapsed Neuroblastoma
- (2013) Daniel A. Morgenstern et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways
- (2013) Roy van der Meel et al. MOLECULAR PHARMACEUTICS
- Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma
- (2012) Yumiko Aoyama et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats
- (2012) Tsuyoshi Minematsu et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein
- (2011) M. Iwai et al. DRUG METABOLISM AND DISPOSITION
- Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe
- (2011) Fieke Lamers et al. ENDOCRINE-RELATED CANCER
- Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression
- (2011) Fieke Lamers et al. EUROPEAN JOURNAL OF CANCER
- Targeted drug delivery to tumors: Myths, reality and possibility
- (2011) You Han Bae et al. JOURNAL OF CONTROLLED RELEASE
- Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
- (2010) M. Tanioka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Recent Advances in Neuroblastoma
- (2010) John M. Maris NEW ENGLAND JOURNAL OF MEDICINE
- Survivin: A new target for anti-cancer therapy
- (2009) Bríd M. Ryan et al. CANCER TREATMENT REVIEWS
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
- (2009) T. Satoh et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- The epidemiology of neuroblastoma: a review
- (2008) Julia E. Heck et al. PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now